Antenatal corticosteroid therapy and risk of osteoporosis

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 105, Issue 5, 1998, Pages 551-555

  Ogueh, Onome ^a   Khastgir, Gautam ^a   Studd, John W W ^a   Jones, Julia ^a   Alaghband Zadeh, Jamshid ^a   Johnson, Mark Richard ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CORTICOSTEROID; DEXAMETHASONE; PROCOLLAGEN C PROTEINASE;

ADULT; ARTICLE; BLOOD LEVEL; BONE METABOLISM; CLINICAL ARTICLE; FEMALE; FETUS LUNG MATURATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; NEONATAL RESPIRATORY DISTRESS SYNDROME; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PREMATURE LABOR; PRIORITY JOURNAL; PROPHYLAXIS;

BIOLOGICAL MARKERS; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; CROSS-LINKING REAGENTS; DEXAMETHASONE; FEMALE; FETAL ORGAN MATURITY; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; LONGITUDINAL STUDIES; LUNG; OBSTETRIC LABOR, PREMATURE; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PEPTIDES; PREGNANCY; PRENATAL CARE; PROCOLLAGEN; PROSPECTIVE STUDIES; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RISK FACTORS;

EID: 0031840142     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1998.tb10157.x     Document Type: Article

References (24)

1. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of respiratory distree syndrome in premature infants. Paediatrics 1972; 50: 515–525.
2. Crowley P. Antenatal corticosteroid therapy: a meta-analysis of ramdomised trials, 1972–1994. Am J Obstet Gynecol 1995; 173: 322–335.
3. Sinclair J. Discussion of Crowley's meta-analysis of randomised controlled trials of antenatal corticosteroids for prevention of respiratory distress syndrome. In: Report of the Consensus Development Conference on the Effects of Corticosteroids for Fetal Maturation on Perinatal Outcomes. Bethesda, LSA: National institute of Health, 1994; 95–96.
4. Baylink DJ. Glucocorticoid-induced osteoporosis. N Engl J Med 1983; 309: 306–308.
5. Reid IR. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 1989; 30: 83–103.
6. Cutroneo KR, Rokowski R, Counts DF. Glucocorticoids and collagen synthesis: comparison of in vivo and cell culture studies. Coll Relat Res 1981; 1: 557–568.
7. Oikarinen AI, Uitto J, Oikarinen J. Glucocorticoid action on connective tissue: from molecular mechanism to clinical practice. Med Biol Eng Comput 1986; 64: 221–230.
8. Godschalk MF, Downs RW. Effects of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 1988; 3: 113–115.
9. Prummel MF, Wiersinga WM, Lips P, Sanders GTB, Sauenvein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991; 72: 382–386.
10. Taylor AK, Lueken SA, Libanati C, Baylink DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am 1994; 20: 589–607.
11. Nielsen HK, Brixen K, Kassem M, Mosekilde L. Acute effect of 1, 25-dihydroxyvitamin D3, prednisone, and 1, 25-dihydroxyvitamin D3 plus prednisone on serum osteocalcin in normal individuals. J Bone Miner Res 1991; 6: 435–441.
12. Caporali R, Gentile S, Caprotti M, Montecucco C. Serum osteocalcin (bone Gla-protein) and steroid osteoporosis in rheumatoid arthritis. J Rheumatol 1991; 18: 148–149.
13. Laan RFJM, van Riel PLCM, van de PPutte LBA, van Eming LJTO, van Hof MA, Lemmens JAM. Low dose prednisolone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomised controlled study. Ann Intern Med 1993; 119: 963–968.
14. Khastgir G, Studd J. Pregnancy-associated osteoporosis. Br J Obstet Gynaecol 1994; 101: 836–838.
15. Melkko J, Niemi S, Risteli J. Radioimmunoassay of the carboxy terminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328–1332.
16. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridoline corss-limnked carboxy terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635–640.
17. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation: correlation to bone histomorphometry. J Bone Miner Res 1993; 8: 127–132.
18. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodelling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Min 1994; 24: 81–94.
19. Puistola U, Risteli L, Kauppila A, Knip M, Risteli J. Markers of type I and type III collagen synthesis in serum as indicators of tissue growth during pregnancy. J Clin Endocrinol Metab 1993; 77: 178–182.
20. Khastgir G, Studd JWW, King H, Abdalla HI, Jones J, Carter G, Alaghband-Zadeh J. Bone changes during pregnancy in women with normal and low bone density. Curr Res Osteoper Bone Miner Meas 1996; 4: 21–22.
21. Canalis EM. Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae. Endocrinology 1983; 112: 931.
22. Lukert BP, Raisz LG. Glucocorticoid induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352–364.
23. Oikarinen A, Autio P, Vuori J et al. Systemic glucocorticoid treatment decreases serum concentrations of carboxy terminal propeptide of type I procollagen and aminoterminal propeptide of type 111 procollagen. Br J Dermatol 1992; 126: 172–178.
24. Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM. Bone density in asthamatic patients taking high dose inhaled and intermittent systemic corticosteroids. Thorax 1992; 47: 414–417.